Rivaroxaban is a type of anticoagulant medication that is commonly used to prevent and treat blood clots in patients with conditions such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation. It works by inhibiting the activity of certain clotting proteins in the blood, thereby reducing the risk of clot formation. Research on rivaroxaban primarily focuses on its efficacy and safety in various patient populations, dosing regimens, and clinical settings. Studies have been conducted to compare rivaroxaban with other anticoagulants, assess its long-term effectiveness, and evaluate its impact on patient outcomes such as bleeding events and stroke prevention. Overall, research on rivaroxaban continues to contribute to our understanding of how this medication can be utilized most effectively in clinical practice to improve patient outcomes and reduce the risk of thrombotic events.